The theme of “less is more” runs throughout the PeopleBeatingCancer site. In other words, less chemo, less radiation, less toxicity is better for the cancer patient. Below, an oncologist talks about follicular lymphoma and how watching and waiting after your diagnosis might be healthier for you than jumping into toxic therapy that can result in no greater overall survival.
While the second article below is referring to conventional therapies, it is important to point out the the top article cites curcumin “is an efficient inducer of apoptosis in Follicular Lymphoma cell lines.”
I am a long-term survivor of a blood cancer called multiple myeloma. I have supplemented with Life Extension Super Bio-Curcumin since 2006. I attribute my long-term CR, in part, by supplementing with several different evidence-based antioxidants such as curcumin.
Have you been diagnosed with lymphoma? To learn more about both conventional (FDA approved) and evidence-based, non-conventional issues, please scroll down the page, post a question or comment and I will reply to you ASAP.
“Conclusion: We have demonstrated for the first time that curcumin is an efficient inducer of apoptosis in FL cell lines, meriting its further evaluation in vivo…”
“Of interest to me was that the watch-and-wait patients and the rituximab-only patients had outcomes that were the same, and there was no difference in survival.”
“The second study was from Philippe Solal-Céligny and the F2-study group, including my friend Massimo Federico. The F2-study is the updated Follicular Lymphoma International Prognostic Index (FLIPI). It was done in the post-rituximab era, whereas FLIPI was done in the pre-rituximab era. They took a database of 1093 people and selected 120 patients who were managed with the watch-and-wait-only approach (80% had advanced-stage disease). Their outcomes (time to treatment failure) were compared with those of 242 patients who were treated with rituximab monotherapy.
They found that for these reasonably comparable patients, the time to treatment failure was the same, supporting a role for watching and waiting. In the accompanying editorial, which was written by me, I described what it is like to discuss watch-and-wait with a patient. In fact, the main reason for watching and waiting with these patients is that we have many new drugs coming down the pike, which may in fact challenge the status quo in patients with limited-stage disease as well as those with advanced-stage disease. We have new monoclonal antibodies, kinase inhibitors, and drugs that affect the microenvironment.
We are in a new era of biological approaches, which I think would be superior to chemotherapy not only in toxicity profile but in their efficacy. Watching and waiting is still reasonable for patients with follicular lymphoma of all varieties because, while we are watching and waiting, clinical trials are ongoing, developing newer and better treatments for these patients.”